Sandoz Will Differentiate To Serve A Different World

 
• By Aidan Fry
  
Generate a summary of this article
Listen to this article
Beta

A differentiated offering that includes biosimilars, value-added medicines and digital health technologies is central to Sandoz’ mission to improve both patient health and its own profit margins, according to CEO Richard Francis.

Rocket
Differentiating its product offering is key to Sandoz' growth taking off • Source: Shutterstock

For all of the miraculous advances of modern medicine, huge healthcare challenges remain, especially in the developing world. “Modern medicine has changed the world, but it has not solved the access issue,” Sandoz’ global head and chief executive, Richard Francis, told delegates to a recent FT Global Pharmaceutical and Biotechnology Conference. “More than two billion people around the world do not have access to the medicines they need.”

And with the world’s population forecast by 2030 to reach 8.5 billion people, of whom 1.4 billion will be aged...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.